First National Bank of Omaha Makes New Investment in Enovis Corporation $ENOV

First National Bank of Omaha purchased a new position in shares of Enovis Corporation (NYSE:ENOV - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 60,369 shares of the company's stock, valued at approximately $1,250,000. First National Bank of Omaha owned approximately 0.10% of Enovis at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Dimensional Fund Advisors LP grew its stake in Enovis by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company's stock valued at $90,156,000 after buying an additional 51,201 shares during the last quarter. Rubric Capital Management LP bought a new position in shares of Enovis during the third quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY raised its holdings in Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock valued at $40,420,000 after acquiring an additional 732,917 shares in the last quarter. River Road Asset Management LLC raised its stake in Enovis by 3.2% in the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company's stock valued at $39,621,000 after purchasing an additional 46,289 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Enovis by 38.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company's stock worth $24,430,000 after acquiring an additional 287,687 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the firm's stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares of the company's stock, valued at $1,120,780.80. The trade was a 2.37% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders purchased 4,200 shares of company stock valued at $92,084 over the last three months. Corporate insiders own 2.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ENOV. Canaccord Genuity Group decreased their target price on Enovis from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Monday. Zacks Research raised Enovis from a "strong sell" rating to a "hold" rating in a research report on Wednesday, July 29th. Wall Street Zen cut Enovis from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. BMO Capital Markets reaffirmed an "outperform" rating and issued a $30.00 price objective on shares of Enovis in a research note on Friday, August 7th. Finally, Wells Fargo & Company lowered their target price on shares of Enovis from $40.00 to $39.00 and set an "overweight" rating for the company in a research note on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Enovis presently has an average rating of "Moderate Buy" and an average target price of $41.29.

Enovis Price Performance

Shares of NYSE:ENOV opened at $26.53 on Thursday. Enovis Corporation has a twelve month low of $19.14 and a twelve month high of $34.28. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -1.38 and a beta of 1.34. The stock's 50 day moving average is $25.04 and its 200-day moving average is $24.11. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same period in the previous year, the firm posted $0.79 earnings per share. The firm's revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts forecast that Enovis Corporation will post 3.15 EPS for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source